Estrogen Receptor alpha

Subscribe to Selected New Research on Estrogen Receptor alpha

2024 relevant articles (42 outcomes, 290 trials/studies) found for this Bio-Agent

Description: One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA.

Also Known As:

ERalpha; Estradiol Receptor alpha; Estrogen Receptor 1; Estrogen Receptors alpha; Receptor alpha, Estrogen; Receptor alpha, Estradiol; alpha, Estradiol Receptor

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 58433

Transcription Factors: 10777

Steroid Receptors: 1476

Estrogen Receptors: 1943

Estrogen Receptor alpha: 2024

human ESR1 protein

Cytoplasmic and Nuclear Receptors: 553

Steroid Receptors: 1476

Estrogen Receptors: 1943

Estrogen Receptor alpha: 2024

human ESR1 protein

Experts

1.	Safe, Stephen: 10 articles (02/2008 - 01/2002)
2.	Davidson, Nancy E: 8 articles (06/2007 - 09/2003)
3.	Leclercq, Guy: 6 articles (09/2008 - 01/2002)
4.	Swaab, Dick F: 6 articles (11/2007 - 10/2002)
5.	Kumar, Rakesh: 6 articles (11/2006 - 10/2002)
6.	Korach, Kenneth S: 6 articles (05/2005 - 05/2002)
7.	Gustafsson, Jan-Ake: 5 articles (10/2008 - 01/2004)
8.	Nardulli, Ann M: 5 articles (09/2008 - 12/2002)
9.	Laurent, Guy: 5 articles (09/2008 - 11/2003)
10.	Uitterlinden, André G: 5 articles (04/2008 - 07/2003)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2009 - "DNA methylation and chromatin remodeling are two epigenetic mechanisms that have been linked with the lack of ERalpha expression and in these cases; demethylation of the ERalpha promoter or treatment with HDAC inhibitors shows promise in restoring ERalpha expression in ERalpha- breast cancers. " 09/01/2009 - "The aim of this study was to determine the methylation status of ERalpha promoter and its possible correlation with clinicopathological features in a series of 138 sporadic breast cancers in Chinese women. " 01/01/2009 - "All of the three ERalpha-positive cell lines used in our study showed colocalization of ERalpha and Ki-67, indicating that these cell lines might be originated from primary tumor cells with autocrine regulation." 08/01/2008 - "AIM: The study aimed to establish the frequency of occurrence of Pvull and Xbal gene polymorphism of estrogen receptor alpha in a group of children and adolescents from north-eastern Poland with diagnosed and treated cancer. " 10/19/2007 - "These studies establish a novel molecular site responsible for Tam- and OHT-ERalpha-induced apoptosis of cancer cells." Order ALL the reference details at left...
2.	Breast Neoplasms (Breast Cancer) 03/01/2002 - "We found that higher doses of AS2O3 dramatically reduced the survival of these two breast cancer cell lines while lower doses of AS2O3 significantly inhibited the expression of estrogen receptor alpha (ER-alpha), but did not effect ER-beta expression. " 01/01/2009 - "The purpose of this study was to explore if the expression of FOXA1 and GATA-3 may provide an opportunity to stratify subsets of patients that could have better outcome, among the ERalpha-negative/poor prognosis breast cancer group. " 09/01/2008 - "Our data suggest that phosphorylation of ERalpha Ser118 and ERalpha Ser167 affects survival in ER-positive breast cancer and could be helpful in distinguishing patients who are likely to benefit from endocrine therapy alone from those who are not." 10/01/2007 - "Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients." 11/01/2009 - "Theses studies suggest amplification of the MT1 gene in some breast tumors and an inverse correlation with ERalpha, PR and MT1 protein expression. " Order ALL the reference details at left...
3.	Carcinoma (Carcinomatosis) 06/01/2009 - "The aim of the present study was to determine the correlations among GPR30, ERalpha, PR, C-erbB-2, p53, TNM stage, and pathologic grade in breast carcinomas. " 04/01/2009 - "This study investigated the immunohistochemical expression of GATA3 in estrogen receptor alpha-positive and estrogen receptor alpha-negative breast carcinomas. " 03/01/2009 - "In this study, 132 canine mammary tumours (46 benign, 86 carcinomas) were examined immunohistochemically for expression of TopBP1, oestrogen receptor alpha (ERalpha), Ki67 and p53. " 09/15/2008 - "RESULTS: To the authors' knowledge, this is the first study to report that ERalpha was phosphorylated in the plasma membrane fractions derived from patients' invasive breast carcinomas. " 01/01/2007 - "This article highlights a recent study by Holst et al. in Nature Genetics that finds estrogen receptor-alpha (ER-alpha) amplification in early benign lesions and more advanced invasive carcinomas of the breast, and discusses the potential implications to our present understanding of the role of ER-alpha in breast tumorigenesis." Order ALL the reference details at left...
4.	Neoplasm Metastasis (Metastasis) 02/01/2007 - "A significant reduction in the incidence of osteolytic bone metastasis was observed by X-ray imaging of the legs and arms of mice inoculated with ERalpha-expressing clones of MDA-MB-231 cells in comparison to controls. " 06/01/2007 - "EGR3 immunoreactivity was positively associated with lymph node status, distant metastasis into other organs, estrogen receptor alpha, or EGR3 immunoreactivity in asynchronous recurrent lesions in the same patients, and was negatively correlated with tubule formation. " 06/01/2005 - "IRS-1 expression in lymph node metastases correlated with neither ERalpha nor Ki-67. " 05/23/2003 - "MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions." 02/01/2007 - "Our study indicates for the first time that stable reintroduction of functional ERalpha in ERalpha-negative human breast cancer cells can inhibit their aggressive bone-metastatic potential in an experimental bone metastasis model." Order ALL the reference details at left...
5.	Adenoma (Adenomas) 03/01/2004 - "Among the ERalpha-positive adenomas, ERalpha values were significantly greater in invasive macroadenomas (80%) than in microadenomas (3.33%). " 03/01/2004 - "ERalpha was significantly more prevalent in controls than in patients with adenomas (37.5 versus 5.7%; p = 0.001); however, the mean ERalpha concentration in adenomas was significantly greater than in controls (42.89 versus 0.024%; p < 0.001). " 06/01/2009 - "Methylation of estrogen receptor 1 in colorectal adenomas is not age-dependent, but is correlated with K-ras mutation." 03/01/2004 - "MIB-1 values did not differ significantly between ERalpha-positive and -negative adenomas, nor did the correlation between ERalpha values and the MIB-1 index attain significance in the total sample, even when only ERalpha-positive adenomas and positive MIB-1 indexes were considered. " 03/01/2004 - "The presence of ERalpha was positive in 9/158 adenomas with a median value for the percentage of labeled cells of 42.89%, and in 6/16 controls (autopsy samples) with a median value for the percentage of labeled cells of 0.024%. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Estrogens (Estrogen)
2.	Estrogen Receptor alpha
3.	Progesterone Receptors (Progesterone Receptor)
4.	Estradiol (Estrace)
5.	Paclitaxel (Taxol)
6.	Protein Isoforms (Isoforms)
7.	Estrogen Receptor beta
8.	Tamoxifen
9.	Estrogen Receptors
10.	Estrogen Receptor Modulators (Antiestrogen)

Related Therapies and Procedures

1.	Adjuvant Chemotherapy
2.	Castration
3.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
4.	Drug Therapy (Chemotherapy)
5.	Heterologous Transplantation (Xenotransplantation)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>